?
ACURASYS
2010 Respiratory
? ICUs
339 patients
Cisatracurium for early ARDS (mod-severe, P/F < 150)
Clinical Question
In patients with moderate-severe ARDS does the early use of a neuromuscular
blocking agent improve mortality?
Critical Appraisal
Key findings
Dec adjusted mortality & less barotrauma, PTX. Lower gen mortality > power
Critique
Use of adjusted mortality for primary outcome not specified on registration.
- Population
- ARDS
- Population Details
- PaO2/FiO2 < 150
- Intervention Arms
-
Early cisatracurium infusion
Cisatracurium 15mg bolus, then 37.5mg/hr for 48 hours - Control Arms
-
Placebo
- Primary Outcome
- Adjusted 90 day mortality
- Secondary Outcomes
- Actual 90 day mortality - no difference , Less barotrauma
- P Value
- 0.04
Outcome Results
Not recorded